NASDAQ: NXTSNexentis Technologies Inc Stock
$2.29+0.00 (+0%)
Updated Jul 20, 2026
NXTS Price
$2.29
Fair Value Price
N/A
Market Cap
$1.67M
52 Week Low
$2.12
52 Week High
$89.79
P/E
-0.1x
P/B
0.13x
P/S
-42.89x
PEG
N/A
Dividend Yield
N/A
Revenue
-$66.00k
Earnings
-$9.39M
Gross Margin
77.3%
Operating Margin
13,028.79%
Profit Margin
14,228.8%
Debt to Equity
0.27
Operating Cash Flow
-$4M
Beta
0.75
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
NXTS Overview
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NXTS's potential to beat the market
- NXTS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Agricultural Input
Industry Rating
B
NXTS
RankedUnranked of 11
RankedUnranked of 11
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $120.46 | B | |
| $5.00 | B | |
| $69.30 | B |
Be the first to know about important NXTS news, forecast changes, insider trades & much more!
NXTS News
Overview
Due Diligence Score
–
Industry Average (33)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NXTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NXTS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NXTS is good value based on its book value relative to its share price (0.13x), compared to the US Agricultural Inputs industry average (1.73x)
P/B vs Industry Valuation
NXTS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NXTS due diligence checks available for Premium users.
Valuation
NXTS fair value
Fair Value of NXTS stock based on Discounted Cash Flow (DCF)
Price
$2.29
Fair Value
$17.55
Undervalued by
86.95%
NXTS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NXTS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.1x
Industry
38.93x
Market
11.71x
NXTS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.13x
Industry
1.73x
NXTS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NXTS's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.6M
Profit Margin
0%
NXTS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NXTS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$16.4M
Liabilities
$3.5M
Debt to equity
0.27
NXTS's short-term assets ($8.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NXTS's short-term assets ($8.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NXTS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NXTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.4M
Investing
-$450.0k
Financing
$2.2M
NXTS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NXTS vs Agricultural Input Stocks
Nexentis Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.